Drug-drug Interactions Between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases
Overview
Psychiatry
Authors
Affiliations
Introduction: The SARS-CoV-2 pandemic with psychiatric comorbidities leads to a scenario in which the use of psychotropic drugs may be required. This requires the support of evidence-based medicine to take into account possible interactions between antidepressants, mood stabilizers, benzodiazepines, and coronavirus infection treatments.
Methods: Three databases were consulted: (a) Lexicomp Drug Interactions, (b) Micromedex Solutions Drugs Interactions, (c)Liverpool Drug Interaction Group for COVID-19 therapies. The CredibleMeds QTDrugs List was also queried. Hydroxychloroquine, chloroquine, azithromycin, lopinavir-ritonavir, remdesivir, favipiravir, tocilizumab, baricitinib, anakinra, and dexamethasone - drugs used for SARS-CoV-2 - were analyzed, and consensus recommendations are made.
Results: The potential interactions of agomelatine, desvenlafaxine, duloxetine, milnacipran, and vortioxetine with COVID-19 treatments shall be considered less risky. Antidepressant interactions with hydroxychloroquine, chloroquine, and azithromycin enhance the risk of QT prolongation, and ECG monitoring is advised for most antidepressants. Antidepressants with lopinavir/ritonavir involve multiple CYP enzyme interactions (except with milnacipran). Gabapentin, oxcarbazepine, pregabalin, topiramate, and zonisamide are safe treatment options that have no significant interactions with COVID-19 treatments. Lithium is contraindicated with hydroxychloroquine, chloroquine, and azithromycin. Precaution should be taken in using valproic acid with lopinavir-ritonavir. The use of benzodiazepines does not present a risk of drug interaction with COVID-19 treatments, except lopinavir/ritonavir.
Conclusions: Clinicians prescribing antidepressants, mood stabilizers/anticonvulsants, and benzodiazepines, should be aware of the probable risk of drug-drug interaction with COVID-19 medications and may benefit from heeding these recommendations for use to ensure patient safety.
Dobrea C, Morgovan C, Frum A, Butuca A, Chis A, Arseniu A J Clin Med. 2025; 14(4).
PMID: 40004740 PMC: 11856802. DOI: 10.3390/jcm14041208.
Kim H, Hong S BMJ Open. 2024; 14(7):e073367.
PMID: 39019633 PMC: 11256064. DOI: 10.1136/bmjopen-2023-073367.
Drug-Drug Interactions Between COVID-19 Treatments and Psychotropic Medications: An Updated Study.
Boppana U, Leonard T, Jolayemi A, Ansari M, Salib A Cureus. 2024; 15(12):e50469.
PMID: 38222143 PMC: 10786447. DOI: 10.7759/cureus.50469.
Rahman M, Al Amin M, Yeasmin M, Islam M Bioinform Biol Insights. 2023; 17:11779322231186481.
PMID: 37461741 PMC: 10350588. DOI: 10.1177/11779322231186481.
Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?.
Pessano Fialho M, Brum E, Oliveira S Inflammopharmacology. 2023; 31(2):633-651.
PMID: 36849853 PMC: 9970139. DOI: 10.1007/s10787-023-01160-w.